The Swiss pharma giant is racking up hits as competitors struggle. Its blood-pressure drug is a bestseller, and more potential blockbusters are in the pipeline. Novartis is also diversified in vaccines, diagnostics, generic drugs, and consumer products. That, along with its lean and effective R&D, should be just the medicine to nurture more success.
